FDA Approves First Generic Once-Weekly Hormone Therapy Patch

The U.S. Food and Drug Administration has approved the first generic version of Climara Pro, a once-weekly transdermal hormone therapy patch. This patch, containing estradiol and levonorgestrel, is intended for women with an intact uterus to treat moderate to severe vasomotor symptoms of menopause and prevent postmenopausal osteoporosis. The approval aims to enhance access to more affordable treatment options for these conditions.